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Abstract. Adult residents of holoendemic malaria regions in Africa have a naturally acquired immunity (NAI) to
malaria that renders them more resistant to new infections, limits parasitemia, and reduces the frequency and severity
of illness. Given such attributes, it is not clear how one might evaluate drug or vaccine efficacy in adults without
serious confounding. To determine symptomatic and asymptomatic malaria attack rates in adults of northern Ghana,
197 men and women underwent curative therapy for any pre-existing malaria infections at the start of the high
transmission (wet) season. They were monitored for first parasitemia and first clinical episode of infection by Plas-
modium falciparum over a 20-week period (May–October 1996). The cumulative incidence of primary infection by
P. falciparum was 0.98 and incidence density of infection was calculated to be 7.0 cases/person-year. Symptoms were
reported by 19.5% of the individuals at the time of first recurrent parasitemia. Incidence of infection, parasite density,
and the frequency of symptoms were comparable in males and females. The results suggest that NAI did not provide
these adults with significant defense against rapid re-infection and suggest that this population-infection design could
serve to demonstrate the efficacy of a drug or vaccine in preventing parasitemia.
INTRODUCTION
Malaria is one of the leading causes of morbidity and
mortality in the tropics, affecting individuals of all ages, but
primarily very young children and pregnant women.1 Inte-
grated approaches against both the parasites and vectors are
required to control this disease with vaccines offering the
best hope for sustained control in areas of intense transmis-
sion.2,3
Malaria morbidity in adult Africans has long been consid-
ered of minor importance4 because adult residents of holo-
endemic areas have usually developed high levels of protec-
tive immunity as a result of their long and continuous ex-
posure to malaria infections. The two forms of immunity
described are 1) an anti-disease immunity that allows one to
carry parasite loads without symptoms, and 2) an anti-par-
asite immunity that is responsible for a marked reduction of
parasite densities after a certain age.5–7 Malaria slides from
adults in highly endemic areas are usually positive regardless
of the clinical context8 and adults are known to become rap-
idly re-infected with malaria parasites after treatment.9 Ap-
propriate criteria for deciding when adults should receive
treatment for malaria have never been agreed upon. It has
been variably suggested that treatment should be based on
parasite density threshold,10 febrile condition,11,12 symptom
history,13 or an association between symptom history and
parasitemia.14,15
The present study was conducted to measure the incidence
and features of symptomatic and asymptomatic infection by
Plasmodium falciparum in malaria-immune adult Ghanaians
who had been radically cured of all pre-existing Plasmodium
infections. Effort was made to study newly incident infec-
tions in comparably sized cohorts of males and females 18–
55 years old who were lifetime residents of the Kassena-
Nankana district of northern Ghana. This study was con-
ducted during the peak malaria transmission season to char-
acterize malaria in the area and to provide the foundation
data needed for valid and efficient design of malaria vaccine
and anti-malarial drug trials in the region.
SUBJECTS AND METHODS
Study site and population. The Kassena-Nankana district
lies within the Guinea savanna woodlands between latitudes
1030 and 1100 north and between longitudes 1000 and
1030 west. It is located in the upper northeast region of
Ghana at its border with Burkina Faso. The Kassena-Nan-
kana district has an area of 1,675 km2 and a population of
140,000 living in roughly 13,000 dispersed compounds. The
main occupation is subsistence farming of predominantly
millet and livestock. The Kassena-Nankana district has a
mean monthly temperature range of 20–45C and rainfall
averages between 800 and 1,000 mm per year, occurring
mainly between May and October. Malaria transmission by
Anopheles gambiae and Anopheles funestus peaks at the
close of wet season (during October and November). Malaria
parasite prevalence among children  5 years old in the
Kassena-Nankana district was significantly greater in the wet
season (May to October) than in the dry season (November
to April).16 Malaria is the leading diagnosis of illness in the
district hospital, accounting for 60% of all admissions and
41% of hospital deaths.17
Subject selection and consent. A representative sample
population of adult men and non-pregnant women between
the ages of 18 and 55 years was sought. The sample was
randomly selected using the Navrongo Demographic Sur-
veillance System, a longitudinal census of all district resi-
dents that is updated every three months.18 We tallied the
total number of eligible adults (48,032) within the four geo-
graphic zones of the district and randomly selected 16 index
compounds, with selections weighted by population size.
Chiefs, elders, and potential subjects were then visited, the
research work was explained and discussed, and opinions
were sought before enrollment. Translation, narration, dis-
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cussion, and communal consent were the essential elements
of the informed consent process.
This research was approved by scientific and ethical re-
view boards of the Ghanaian Ministry of Health and the U.S.
Navy and was conducted in accordance with regulations
governing the protection of human subjects in medical re-
search.
Enrollment and screening. The screening process in-
volved clinical history, vital signs, physical examination by
a physician, collection of 1.0-ml venous blood for malaria
smears, and hematology screening. Urine was collected from
all women for -human chorionic gonadotropin pregnancy
testing. Laboratory screening involved microscopy of Gi-
emsa-stained thick and thin blood smears, hemoglobin test-
ing, and qualitative testing for glucose-6-phosphate dehydro-
genase (G-6-PD) deficiency. Remaining blood and plasma
were archived for future laboratory work. Specific exclusion
criteria were pregnancy, allergic reaction to antimalarial
drugs, and illness or a condition requiring hospitalization.
Radical cure therapy of malaria. Just prior to the start
of the rainy season (April 1996), radical cure therapy was
used to achieve complete clearance of any patent, dormant,
or incubating malaria infection from blood and liver. Vol-
unteers were treated with oral quinine sulfate (650 mg three
times a day for four days) followed by doxycycline, (100
mg twice a day for 10 days). Subjects testing normal for G-
6-PD (NADP spot test; Sigma Chemical Co., St. Louis,
MO) received primaquine (0.5 mg base/kg of body weight
once a day for 14 days). Nineteen subjects who tested as
deficient for G-6-PD received only quinine and doxycycline
treatment. All doses were supervised and directly observed
over the 18 days of radical curative or 14 days of curative
therapy.
Surveillance and referral. Routine blood films were ob-
tained on day 15 of the initial treatment and were repeated
at two-week intervals for the duration of the study (20
weeks) by trained fieldworkers permanently residing in each
of the 16 compound clusters. Fieldworkers visited subjects
three times a week at their homes to inquire of their general
health and check for fever by measuring axillary tempera-
ture. Each visit began with a direct question: ‘‘Have you
been sick since the last visit?’’ If the answer was no, the
interview ended. If the answer was yes, the subject was
asked to describe his or her symptoms and these were re-
corded. If a subject complained of current illness to the field-
worker or had an axillary temperature  37.5C, a non-rou-
tine blood film was obtained. Subjects were transported to
the district hospital where the blood smear was examined by
an expert malaria microscopist. Based upon presenting signs,
symptoms, and microscopy results, physicians decided upon
a treatment plan.
Study end points, treatment, and follow-up. The two
primary outcome variables in this study were 1) time to the
primary post-cure parasitemia and 2) time to the first episode
of parasitemia associated with clinical symptoms. Blood
slides were prepared as Giemsa-stained thick and thin
smears examined by 1,000 light microscopy using oil im-
mersion. Parasitemias were scored per microliter of blood
by counting the number of asexual parasites per 200 white
blood cells, assuming 8,000 white blood cells per microliter,
and multiplying the parasite count by 40. A slide was con-
sidered negative if no parasites were observed within 100
high-power fields.
Our working diagnosis of clinical malaria was a patent
asexual stage parasitemia accompanied by any one or more
of the following symptoms: fever, headache, chills, myalgia,
dizziness, nausea, and diarrhea. All symptomatic subjects
with microscopy-confirmed malaria were promptly treated
with chloroquine diphosphate (25 mg base/kg of body
weight over a 48-hr period) and monitored for outcome.
Chloroquine failures were treated with three tablets of Fan-
sidar (500 mg of sulfadoxine plus 25 mg of pyrimethamine;
F. Hoffman-La Roche, Basel, Switzerland).
Data handling and analysis. Cumulative incidence (CI),
expressed as the risk of an outcome and/or probability of
infection during the 20 weeks, and incidence density (ID),
which estimates new infections per unit of person-time at
risk, were used as quantitative tools in determining the fre-
quency of newly incident Plasmodium infections in this co-
hort. Due to the pre-erythrocytic stage incubation period of
the parasite, the first 10 days following curative therapy were
excluded from analyses as risk-free person-time. To identify
predictors of a positive blood slide, and to determine wheth-
er the use of specific complaints or combinations of com-
plaints significantly increased the likelihood of correctly pre-
dicting a positive blood smear, we used logistic regression
models that fitted parasite positivity against symptoms re-
corded. The multivariate interactions among reported symp-
toms and parasitemia were investigated by graphical mod-
eling19 using the MIM 3.0 software.20 The best fitting model
was determined by means of a backwards elimination pro-
cedure and a less stringent cutoff value of P  0.1 was
applied to improve the likelihood of finding associations giv-
en a small sample size.
RESULTS
The study plan is chronologically depicted as a flow dia-
gram in Figure 1. During the initial radical or curative ther-
apy stage, 98.7% of the 16,758 drug doses were adminis-
tered and witnessed with only one volunteer dropping out.
The baseline characteristics of the enrolled study population
that completed radical or curative treatment and contributed
person-time and/or study endpoints are presented in Table 1.
The mean age, weight, and hemoglobin concentration among
females was significantly different from that of males; older
age was possibly an artifact that arose from the necessity of
restricting female enrollment to those not pregnant or nurs-
ing. Patent malaria infections were identified in 110 (55.8%)
of 197 subjects at enrollment and P. falciparum accounted
for 102 (92.7%) of the 110 malaria infections, with the re-
maining 7.3% due to infections by P. malariae (7) and P.
ovale (1). Gametocytes were observed in 29.6% of these
subjects. Glucose-6-phosphate dehydrogenase deficiency
was detected in 19 (9.6%) of the 197 enrolled subjects (7.1%
of the women versus 11.6% of the men: P  0.28). Baseline
malaria prevalence was significantly greater among males
(58% versus 38%; P  0.01). All subjects belonged to the
two main ethnic groups (Kasssim and Nankam), in near bal-
anced numbers, and had lived their entire lives in the area.
Blood smear screening on day 15 following the start of
radical or curative therapy demonstrated parasite clearance
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FIGURE 1. Study plan.
TABLE 1
Baseline characteristics of the Ghanaian study population*
Characteristic Males Females P
No. of subjects (%)
Mean age (years) (95% CI)
Mean weight (kg) (95% CI)
Mean Hb level (g/dl) (95% CI)
No. Plasmodium falciparum positive (%)
112 (56.8)
35.4 (33.3–37.5)
57.4 (56.0–58.8)
12.1 (11.8–12.4)
64 (57.1)
85 (43.1)
43.3 (41.3–45.2)
50.3 (49.0–51.6)
10.8 (10.3–11.2)
33 (38.8)
–
0.01
0.01
0.01
0.01
GM parasitemia/l (95% CI)
No. febrile (%)
135 (103–177)
2 (1.0)
98 (78–123)
1 (0.5)
0.07
–
* CI  confidence interval; Hb  hemoglobin; GM  geometric mean.
in all subjects. The first infections thereafter were identified
during week 3 of post-cure follow-up. The cumulative in-
cidence of primary P. falciparum infection over the 20
weeks following cure are plotted for males and females in
Figure 2. Both sexes demonstrated the most profound in-
crease in new infections during weeks 5–10, when the CI
increased from 0.22 to 0.81 in males and 0.21 to 0.77 in
females. Three subjects remained consistently aparasitemic
to the 20-week endpoint. Four others dropped out of the
study (negative) at various earlier time points. The collective
20-week CI for P. falciparum infection in adults was 0.98.
The respective 20-week wet season IDs for infection in
males and females was 7.2 and 6.7 (relative risk [RR] 
1.07, 95% confidence interval  0.70–1.24) infections/per-
son-year. The CI of illness coincident with parasitemia dur-
ing this period was 0.42 among males and 0.49 among fe-
males (Figure 2). Analysis by location (Figure 3) found the
acquisition of primary infection to be most rapid in the west-
ern compounds and slowest in the south (mean time to in-
fection: west  7.2 weeks versus south  8.7 weeks; P 
0.03). Mean times to the first episode of confirmed symp-
tomatic malaria were similar among the four locations stud-
ied.
Table 2 shows the characteristics of these primary infec-
tions in male and female subjects. There were no statistically
significant differences between sexes for either CI, ID, the
frequency of symptomatic primary infections, or the geo-
metric mean (GM) density of parasitemias. Irrespective of
sex, adults experienced a 20-week wet season ID of 7.0
(95% confidence interval  5.1–6.8) new P. falciparum in-
fections per person-year of exposure. There were four fe-
males (4.7%) and three males (3.6%) who did not develop
a detectable parasitemia during their 8–20-week participa-
tion. All were G-6-PD normal. One of these subjects was
infected with P. falciparum at enrollment, two others with
P. malariae, and six of the seven made voluntary clinic vis-
its for diagnosis and treatment of illness during the study
period. Analysis by age, which divided the population into
two near equal groups,  40 years old (n  100) and  40
years old (n  97), revealed that mean times to parasitemia
and symptomatic parasitemia in the older age group were
both significantly delayed (P  0.01) relative to those in the
younger group (Figure 4). As a result, wet season ID in the
older group was 5.8 infections/person-year compared with
7.1 in the younger group (P  0.17). Parasite densities at
infection and at the time of symptoms were similar in the
two groups.
There were 190 primary, post-cure infections by P. fal-
ciparum during the 20 weeks following cure. Symptoms and
physical complaints characterized the first appearance of par-
asites in 37 (19.5%) of these 190 infections. Comparable
proportions of males and females were symptomatic at this
first parasitemia (males: 22 of 109  20.2%; females: 15 of
81  18.5%). Fever was present in eight (21.6%) of the 37
primary infections that presented with clinical illness, but
was not associated with the level of parasitemia. Among
individuals with asymptomatic primary parasitemias who
were not treated, asexual stage parasites were variably pre-
sent in subsequent follow-up slides. Parasitemia was detect-
ed in 65% of 566 follow-up slides from 113 representative
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FIGURE 2. Cumulative incidence after radical cure of primary Plasmodium falciparum infections and of P. falciparum infections with
symptoms in adult males and females in the wet season (May–December 1996) in northern Ghana.
FIGURE 3. Cumulative incidence after radical cure of primary
Plasmodium falciparum infections by location in the Kassena-Nan-
kana District of northern Ghana during the wet season (May–De-
cember 1996).
subjects and usually not detected over more than three con-
secutive examination dates. During the course of study time
applied to the 153 infected-asymptomatic volunteers, there
were 242 occasions, judged to be clinical malaria on the
basis of signs and symptoms that prompted blood smear ex-
amination. Asexual stage parasites of P. falciparum were
present at 62 of these 242 occasions and those of P. malariae
were present in one case. Asexual stages of P. falciparum
were thus associated with 99 of 279 cases of malaria-like
illness in these previously cured adults. The frequencies of
specific complaints/symptoms associated with these infec-
tions are plotted against those of 180 other cases where par-
asites were undetected (Figure 5). The frequency of dizzi-
ness, chills, and headache were significantly greater among
those with a confirmed parasitemia.
Stepwise logistic regression that was applied to the data
revealed dizziness and myalgia as potential (P  0.1) pre-
dictors of a positive blood slide, while diarrhea was unre-
lated. The multivariate dependencies among parasitemia and
reported symptoms were further investigated using graphical
modeling. This approach showed dizziness and myalgia to
be directly linked to parasitemia, with diarrhea independent
of all other variables. The other reported symptoms (chills,
nausea, headaches, and fever) were independent of the par-
asitemia given a presentation of dizziness and/or myalgia.
Patients who reported chills or nausea were likely to also
report dizziness or myalgia, but rarely both. Headache and
fever were independent of the other symptoms given the
presence of chills.
Table 3 shows the range and GM densities of primary
post-cure P. falciparum parasitemias that were measured in
symptomatic and asymptomatic cases. Relatively low-den-
sity parasitemias characterized more than 85% of the infec-
tions and were associated with physical complaints. The den-
sity of asymptomatic parasitemias at first appearance of in-
fection was no different than the density of parasitemia later
associated with the first occasion of clinical illness following
curative treatment. There were no significant differences be-
tween sexes, or between symptomatic and asymptomatic
cases in the frequency of high parasitemias or in the GM
densities of parasitemias.
DISCUSSION
The results of this study show that wet season malaria
transmission in the Kassena-Nakana district of northern Gha-
na is intense and that the incidence of infection and clinical
illness associated with malaria in adults is virtually identical
in males and females. Despite a natural immunity derived
from a lifetime of intense exposure, our results demonstrate
that adults become rapidly re-infected and parasitemic fol-
lowing effective radical cure treatment. Neither genetic re-
sistance nor long-acquired immunity appears to be sufficient-
ly strong or widely present in this population to completely
inhibit parasitemia. Rapid re-infection and patency among
treated malaria-immune adults was recognized more than a
decade ago in western Kenya.9 This general susceptibility
and rapid appearance of low-density blood stage infections
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TABLE 2
Characteristics of first infections with Plasmodium falciparum after radical cure in adult male and female study subjects during the wet season
(May–December 1996) in northern Ghana*
Characteristic Males Females P
Person-weeks at risk
No. with primary P. falciparum infections/total subjects (%)
No. symptomatic at first positive slide/total positive subjects (%)
Cumulative incidence/20 weeks of the wet season
Incidence density/person-year
777
109/112 (97.3)
22/109 (20.2)
0.99
7.3
629
81/85 (95.3)
15/81 (18.5)
0.97
6.7
–
0.45
0.77
–
0.56
GM parasitemia/l—first appearance—Asymptomatic (95% CI)
GM parasitemia/l—first appearance—Symptomatic (95% CI)
129 (96–169)
451 (171–1,190)
162 (118–223)
347 (131–921)
0.27
0.72
* GM  geometric mean; CI  confidence interval.
FIGURE 4. Mean time to primary infection by Plasmodium fal-
ciparum and primary symptomatic infection by age group in adult
Ghanaians. Error bars indicate 95% confidence intervals.
FIGURE 5. Comparative physical complaints/symptoms reported
by adult Ghanaians with positive or negative malaria blood smears.
* Indicates a statistically significant difference between groups.
may result from the ineffectiveness of anti-sporozoite and
anti-liver stage immunity or to an asexual blood stage effect
coupled with a pre-erythrocytic stage immunity that reduces
but does not completely eliminate all infected hepatocytes.2,9
In spite of comparable malaria attack rates measured in
adult males and females, the relatively small size and eco-
logical uniformity of the Kassena-Nakana district study area,
and seasonal climatic conditions that impinge evenly, there-
by smoothing over ecologic and hydrologic differences, our
analysis identified a significant difference between locations
in the mean time to infection. This difference may relate to
the geographic concentration of well-established irrigation
systems in the western compounds. If this was not due to
chance, it is likely that even more highly significant differ-
ences between locations will exist in the Kassena-Nakana
district during dry season conditions. This observation may
be supported by location analysis of data from recent studies
conducted during the wet and dry season using infant co-
horts. Drug and vaccine efficacy trials might be intentionally
focused within particular areas of the Kassena-Nakana dis-
trict to achieve rapid endpoints and tight confidence inter-
vals.
Contrary to expectations, the ID of primary parasitemia
in this adult cohort was virtually identical to that of a loca-
tion-matched cohort of infants (6–24 months old) who were
treated and followed through 20 weeks of wet season in the
following year (Adult ID  7.03 infections/person-year ver-
sus Infant ID  7.06 infections/person-year; RR  0.99,
95% confidence interval  0.82–1.19).21 The cumulative in-
cidence profiles of adult and infant cohorts indicate the same
rapid increase and plateau effect. Among infants, the most
rapid increase in incidence occurred between five and 10
weeks with a plateau reached at week 10 that incremented
only slightly more by the 20-week endpoint. In an analogous
manner, new infections among adults increased most steeply
from weeks 5 (male CI  0.22, female CI  0.21) to 10
(male CI  0.81, female CI  0.77). Among infants, only
18 new infections occurred in weeks 11–20, leaving 2.3%
of the wet season cohort parasite-free. In a similar manner,
the adult CI was 0.88 in week 13 and only 18 additional
subjects (9.5% of the infected cohort) developed patent in-
fections during the ensuing seven weeks of study.
We assumed that adult life-long residents of Navrongo, in
contrast to their young children, would manifest a lower or
delayed incidence of patent re-infection, lighter parasitemias
at the time of re-infection, and mild or negligible illness. We
found lighter parasitemias and decreased clinical manifes-
tations in adults, but a near identical rate of re-infection fol-
lowing radical cure. A lower attack rate in adults might have
been observed had both cohorts been studied simultaneously,
but was not apparent in our comparison of wet season IDs
for adults during 1996 and for infants during 1997. Height-
ened transmission impacting upon adults, or reduced trans-
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TABLE 3
Range and geometric mean densities of first Plasmodium falciparum infections after radical cure in adult Ghanaians
Parasitemia range (/l blood)
Asymptomatic
Males Females
Symptomatic
Males* Females†
2,000
2,000–9,999
10,000–19,999
	20,000
Combined
82
3
2
0
87
64
1
0
1
66
40
3
2
2
47
46
5
0
1
52
GM parasitemia (range) 129 (40–12,560) 162 (40–31,640) 199 (40–97,680) 200 (40–22,000)
* Males: 22 symptomatic at first positive slide; 25 of 87 others (initially asymptomatic-positive) later became symptomatic-positive.
† Females: 15 symptomatic at first positive slide; 37 of 66 others (initially asymptomatic-positive) later became symptomatic-positive.
mission experienced by the infant cohort may have obscured
real differences attributable to age-dependent immunity.
Interestingly, in contrast to the near equal incidence den-
sity seen in adults and children, we observed among adults
that the 	 40-year-old age group had a lower ID of re-in-
fection compared with those  40 years old, suggesting an
effective age-dependent, naturally-acquired immunity. Under
identical conditions of risk, an anti-parasite immunity ca-
pable of barring certain genotypes and suppressing parasit-
emia to sub-clinical levels in adults would be expected to
prevent or delay the patency of primary infections relative
to those sustained by infants.
As expected, adults experienced parasite densities and fe-
brile episodes that were considerably reduced from those
recorded in the infant cohorts.21 It was interesting to note
that many of the infected Ghanaian adults in the present
study experienced episodes of illness that corresponded with,
and may have arisen from, their P. falciparum infections.
We concede that the exclusive role of the parasitemias as a
cause of their illness cannot be ascertained with certainty
since the same signs and symptoms were reported frequently
by these same individuals in the absence of parasites. How-
ever, the 37 occasions of illness that corresponded precisely
with the first appearance of parasites following radical cure
are most probably the true result of infection. Literature on
the subject of adult malaria implies that adults with lifelong
exposure to malaria do not become ill when they become
re-infected with malaria parasites.4,12 Our data suggest that
this may not be the case when parasites have been complete-
ly cleared. Interesting recent consideration has been given to
the impact of liver schizonticidal therapy upon protective
immunity elicited by immunization of mice with radiation-
attenuated sporozoites,22 and to the potential loss of premu-
nition in clinically immune adults who have undergone such
curative therapy to eliminate their ‘‘benign’’ chronic malaria
infections.23
None of the adult patients became severely ill, but they
reported physical complaints that limited their capacity to
function normally, prompting them to interrupt their usual
routine and seek medical care. Most of the symptoms ob-
served were rather nonspecific. However, there were signif-
icant differences between parasitemic and non-parasitemic
patients that may not have been due entirely to chance. Al-
though we did not undertake or power this investigation to
test a specific hypothesis of adult clinical predictors of par-
asitemia, we found dizziness and myalgia to be the best mul-
tivariate predictors of parasitemia. This pattern was con-
firmed when multivariate interactions between different
symptoms and parasitemia were investigated. Parasitemia
was directly linked only to dizziness and myalgia, which in
turn were likely to occur in combination with chills or nau-
sea. This is in contrast to other studies that did not find
symptom reports useful in diagnosing clinical malaria.8 Our
preliminary findings suggest that adults presenting with diz-
ziness or myalgia in association with chills and headache are
likely to be parasitemic. We believe that this graphical ap-
proach to the identification of key physical complaints and
symptoms associated with parasitemias should be tested
more rigorously.
The incidence data herein reported for adult males and
females provides the necessary foundation for rational de-
sign of trials to evaluate drug or vaccine effects. Although
African infants and pregnant women will certainly be the
target population for vaccination when an effective product
becomes deliverable, adults and school children will proba-
bly be the earliest recipients, in whom safety, tolerance, and
infection-blocking qualities can be readily assessed. In this
regard, it was important to demonstrate near universal sus-
ceptibility to re-infection and its rapid manifestation as pat-
ent parasitemias in adult Ghanaian males and females. Ad-
ditionally important in planning such studies is our docu-
mentation of radical cure compliance and dropout rates, the
proportion of radically cured subjects who dropped out prior
to yielding an endpoint, and the frequency and nature of
illness that developed coincident with re-infection. Applying
our findings of an 80% attack rate within 12 weeks to a
prospective 12-week trial of a drug/vaccine with predicted
75% protective efficacy (PE), and an 80% probability (pow-
er) of having the lower 95% confidence limit for that PE 
70%, we would require a population of 1,004 adults. With
these variables kept the same, but with the lower 95% con-
fidence limit relaxed to  60% for the PE, we would need
only to enroll 151 subjects.
In conclusion, this study has shown that Ghanaian adults
of the northern Kassena-Nakana district experience a sea-
sonal ID of infection by P. falciparum that was comparable
with that of infants living in the same communities. Within
the 20-week wet season, virtually all adults had manifested
a patent primary infection and many reported illness that
coincided with parasitemia. Adults experienced predomi-
nantly low-density infections, characterized by mild clinical
illness. Dizziness, myalgia, chills, fever, and headache were
the most commonly reported symptoms that prompted health
clinic visits seeking medical care. This study provides the
foundation for designing efficient, practical clinical trials and
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preventive strategies against malaria in this holoendemic re-
gion.
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